HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study.

AbstractBACKGROUND:
Cachexia is a common problem in patients (pts) suffering from upper gastrointestinal cancer. In addition, most of these patients suffer from malabsorption and stenosis of the gastrointestinal tract due to their illness. Various methods of supplementary nutrition (enteral, parenteral) are practised. In patients with advanced pancreatic cancer (APC), phase angle, determined by bio-electrical impedance analysis (BIA), seems to be a survival predictor. The positive influence of BIA determinate predictors by additional nutrition is currently under discussion.
METHODS:
To examine the impact of additional parenteral nutrition (APN) we assessed outpatients suffering from APC and progressive cachexia. The assessment based on the BIA method. Assessment parameters were phase angle, ECM/BCM index (ratio of extracellular mass to body cell mass), and BMI (body mass index). Patients suffering from progressive weight loss in spite of additional enteral nutritional support were eligible for the study.
RESULTS:
Median treatment duration in 32 pts was 18 [8-35] weeks. Response evaluation showed a benefit in 27 pts (84%) in at least one parameter. 14 pts (43.7%) improved or stabilised in all three parameters. The median ECM/BCM index was 1.7 [1.11-3.14] at start of APN and improved down to 1.5 [1.12-3.36] during therapy. The median BMI increased from 19.7 [14.4-25.9] to 20.5 [15.4-25.0]. The median phase angle improved by 10% from 3.6 [2.3-5.1] to 3.9 [2.2-5.1].
CONCLUSIONS:
We demonstrated the positive impact of APN on the assessed parameters, first of all the phase angle, and we observed at least a temporary benefit or stabilisation of the nutritional status in the majority of the investigated patients. Based on these findings we are currently investigating the impact of APN on survival in a larger patient cohort.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT00919659.
AuthorsUwe Pelzer, Dirk Arnold, Mehmet Gövercin, Jens Stieler, Bernd Doerken, Hanno Riess, Helmut Oettle
JournalBMC cancer (BMC Cancer) Vol. 10 Pg. 86 (Mar 09 2010) ISSN: 1471-2407 [Electronic] England
PMID20214798 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Aged
  • Body Mass Index
  • Cachexia (complications, therapy)
  • Cohort Studies
  • Electric Impedance
  • Female
  • Humans
  • Male
  • Medical Oncology (methods)
  • Middle Aged
  • Nutritional Status
  • Palliative Care (methods)
  • Pancreatic Neoplasms (complications, therapy)
  • Parenteral Nutrition (methods)
  • Quality of Life

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: